|
1
|
Ghoncheh M, Pournamdar Z and Salehiniya H:
Incidence and mortality and epidemiology of breast cancer in the
world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu FC, Lin HT, Kuo CF, See LC, Chiou MJ
and Yu HP: Epidemiology and survival outcome of breast cancer in a
nationwide study. Oncotarget. 8:16939–16950. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Palomeras S, Ruiz-Martinez S and Puig T:
Targeting breast cancer stem cells to overcome treatment
resistance. Molecules. 23:21232018. View Article : Google Scholar
|
|
4
|
Lorusso V, Manzione L and Silvestris N:
Role of liposomal anthracyclines in breast cancer. Ann Oncol. 18
(Suppl 6):vi70–vi73. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cabeza L, Ortiz R, Arias JL, Prados J,
Ruiz Martínez MA, Entrena JM, Luque R and Melguizo C: Enhanced
antitumor activity of doxorubicin in breast cancer through the use
of poly(butylcyanoacrylate) nanoparticles. Int J Nanomedicine.
10:1291–1306. 2015.PubMed/NCBI
|
|
6
|
Kerr JS and Wilson CH: Nuclear
receptor-binding protein 1: A novel tumour suppressor and
pseudokinase. Biochem Soc Trans. 41:1055–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yasukawa T, Tsutsui A, Tomomori-Sato C,
Sato S, Saraf A, Washburn MP, Florens L, Terada T, Shimizu K,
Conaway RC, et al: NRBP1-containing CRL2/CRL4A regulates amyloid β
production by targeting BRI2 and BRI3 for degradation. Cell Rep.
30:3478–3491.e6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Q, Zhou X, Li P, Wang W, Wang J, Tan M,
Tao L and Qiu J: High NRBP1 expression promotes proliferation and
correlates with poor prognosis in bladder cancer. J Cancer.
10:4270–4277. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruiz C, Oeggerli M, Germann M, Gluderer S,
Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T,
Stürm S, et al: High NRBP1 expression in prostate cancer is linked
with poor clinical outcomes and increased cancer cell growth.
Prostate. 72:1678–1687. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei H, Wang H, Ji Q, Sun J, Tao L and Zhou
X: NRBP1 is downregulated in breast cancer and NRBP1 overexpression
inhibits cancer cell proliferation through Wnt/β-catenin signaling
pathway. Onco Targets Ther. 8:3721–3730. 2015.PubMed/NCBI
|
|
11
|
Miettinen M, Wang Z, McCue PA,
Sarlomo-Rikala M, Rys J, Biernat W, Lasota J and Lee YS: SALL4
expression in germ cell and non-germ cell tumors: A systematic
immunohistochemical study of 3215 cases. Am J Surg Pathol.
38:410–420. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen T, Tsang JYS, Su XC, Li P, Sun WQ,
Wong ILK, Choy KY, Yang Q, Tse GMK, Chan TH and Chow LMC: SALL4
promotes tumor progression in breast cancer by targeting EMT. Mol
Carcinog. 59:1209–1226. 2020. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu C, Yao F, Mao X, Li W and Chen H:
Effect of SALL4 on the proliferation, invasion and apoptosis of
breast cancer cells. Technol Cancer Res Treat.
19:15330338209800742020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dirican E and Akkiprik M: Functional and
clinical significance of SALL4 in breast cancer. Tumour Biol.
37:11701–11709. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan JH, Li WX, Hu C and Zhang B:
Upregulation of SNHG12 accelerates cell proliferation, migration,
invasion and restrain cell apoptosis in breast cancer by enhancing
regulating SALL4 expression via sponging miR-15a-5p. Neoplasma.
67:861–870. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hesari A, Anoshiravani AA, Talebi S,
Noruzi S, Mohammadi R, Salarinia R, Zare R and Ghasemi F: Knockdown
of sal-like 4 expression by small interfering RNA induces apoptosis
in breast cancer cells. J Cell Biochem. 120:9392–9399. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Method. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Liu N, Xu D, Wu B, Wu X, Sun X,
Yang Y and Yan F: Hsa-miR-599 inhibits breast cancer progression
via BRD4/Jagged1/Notch1 axis. J Cell Physiol. 237:523–531. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang K, Zhong H, Li N, Yu N, Wang Y, Chen
L and Sun J: Discovery of novel anti-breast-cancer inhibitors by
synergistically antagonizing microtubule polymerization and aryl
hydrocarbon receptor expression. J Med Chem. 64:12964–12977. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang D, Zheng Q, Wang C, Zhao N, Liu Y
and Wang E: BHLHE41 suppresses MCF-7 cell invasion via MAPK/JNK
pathway. J Cell Mol Med. 24:4001–4010. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan EH and Sansom OJ: A new tumour
suppressor enters the network of intestinal progenitor cell
homeostasis. EMBO J. 31:2444–2445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wilson CH, Crombie C, van der Weyden L,
Poulogiannis G, Rust AG, Pardo M, Gracia T, Yu L, Choudhary J,
Poulin GB, et al: Nuclear receptor binding protein 1 regulates
intestinal progenitor cell homeostasis and tumour formation. EMBO
J. 31:2486–2497. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hupfeld T, Chapuy B, Schrader V, Beutler
M, Veltkamp C, Koch R, Cameron S, Aung T, Haase D, Larosee P, et
al: Tyrosinekinase inhibition facilitates cooperation of
transcription factor SALL4 and ABC transporter A3 towards intrinsic
CML cell drug resistance. Br J Haematol. 161:204–213. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
